Wegovy comorbidities: which conditions change your eligibility and what the evidence shows

You've been told your BMI might not be high enough — but you have other conditions

This is one of the questions our prescribers hear regularly. Someone has a BMI of 28, they've been living with high blood pressure or sleep apnoea for years, and they've read that Wegovy is for people with a BMI of 30 or above. The confusion is understandable, but the picture is more nuanced than a single number suggests.

The licensed eligibility for Wegovy in the UK runs in two tracks. Adults with a BMI at or above 30 can be considered for the medicine on the basis of weight alone. Adults with a BMI between 27 and 29.9 are also within the licensed indication, provided at least one weight-related condition is documented. In that lower BMI band, the comorbidity isn't a bonus consideration; it's what brings you inside the licence at all. The NHS medicines page for semaglutide sets this out clearly alongside the other criteria a prescriber will consider.

The conditions most often cited in clinical practice include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol or triglycerides (dyslipidaemia), obstructive sleep apnoea, and established cardiovascular disease. Osteoarthritis of the knees or hips (where excess weight is mechanically driving the problem) is also recognised. No single list is exhaustive: what matters is whether the prescriber judges your condition to be clinically linked to your weight. A quick habit worth building before your consultation is writing down every current diagnosis and current medication, including over-the-counter items. It takes less than a minute and makes the clinical review far more accurate.

What NICE says about comorbidities and NHS eligibility for Wegovy

The NICE technology appraisal for semaglutide (Wegovy) sets a higher bar for NHS access than the licence itself. Under NICE TA875, NHS commissioners are asked to fund Wegovy for adults with a BMI of 35 or above and at least one weight-related comorbidity, used for a maximum of two years within a specialist weight management service that provides multidisciplinary support. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the equivalent threshold is 2.5 kg/m² lower throughout.

This means two things are true at once. Someone with a BMI of 28 and sleep apnoea is within the licensed indication for private prescription, but would not meet the NICE threshold for NHS funding. Someone with a BMI of 35 and type 2 diabetes may meet both. Neither situation is straightforward to navigate without clinical input, which is why the comorbidities a person carries need to be assessed rather than self-scored against a checklist.

NICE also advises that treatment should be reviewed if less than 5% of body weight has been lost after six months at the maintenance dose. The comorbidities context matters here too: some people experience meaningful improvements in blood pressure or blood glucose markers before the scales move as far as the 5% threshold, and those outcomes are part of what prescribers track.

For a broader look at how weight-related conditions interact with Wegovy eligibility, the weight-related comorbidity and Wegovy guide covers the clinical detail in depth.

Wegovy's cardiovascular indication, a separate but connected story

In 2024 the MHRA granted Wegovy an additional licence in the UK, covering the reduction of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and a BMI of 27 or above. This isn't the same as the weight management licence, and it isn't a reason to seek Wegovy independently as a heart-disease treatment. What it does mean is that the clinical evidence behind semaglutide extends well beyond weight loss numbers.

The SELECT trial, which underpinned the cardiovascular licence, enrolled adults who already had heart disease (not diabetes) and found that semaglutide 2.4 mg reduced the rate of major cardiovascular events over roughly three years. That trial population had significant comorbidities by design. Researchers have also explored whether semaglutide may offer benefits beyond cardiovascular risk reduction, and our guide on whether Wegovy has anti-inflammatory properties looks at what the emerging evidence suggests. The finding reinforces the clinical framing that Wegovy isn't just a weight loss tool for people who happen to have health problems: in some cases, the health problems are precisely the reason the medicine is prescribed.

If you're exploring treatment options and want to understand how cost fits into the picture alongside the clinical rationale, the Wegovy price comparison for UK patients offers honest context on what private treatment covers and why the cheapest listing rarely reflects the full picture for a prescription medicine.

What the prescriber actually assesses at consultation

Comorbidities don't work like a ticket in a queue. A prescriber reviewing a consultation isn't simply checking boxes, they're reading the interaction between conditions, current medications, and the risks that matter for this individual. Someone with type 2 diabetes already taking GLP-1 receptor agonists for glucose control needs a different conversation from someone with sleep apnoea and no current treatment. Someone on multiple antihypertensives, where weight loss may eventually allow dose reduction, is in a different position again.

There are also conditions that require care or rule treatment out. A personal or close family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia type 2, are contraindications listed in the prescribing information. A history of pancreatitis requires careful discussion. Severe gastrointestinal conditions may affect suitability. These aren't reasons to assume you can't be treated; they're reasons to be thorough. The semaglutide overview covers the pharmacology and the clinical context in more detail for those who want to go deeper before their consultation.

At nume (at our GPhC-registered pharmacy) every consultation is read by a GPhC-registered Independent Prescriber the same day. The comorbidities you list, the medications you're taking, and the history you provide all feed directly into that clinical review. There's no algorithm making the call. If you want to understand the practical side of treatment before you begin, our guide on how to apply Wegovy walks through the injection process step by step. If you're ready to have that conversation properly, you can start your free consultation and have your clinical picture reviewed today.